PLX4032
- CAS NO.:918504-65-1
- Empirical Formula: C23H18ClF2N3O3S
- Molecular Weight: 489.92
- MDL number: MFCD18074504
- SAFETY DATA SHEET (SDS)
- Update Date: 2023-06-30 15:45:59
![PLX4032 Structural](https://img.chemicalbook.in/CAS/GIF/918504-65-1.gif)
What is PLX4032?
Absorption
Vemurafenib is well absorbed after oral administration. Peak concentrations are reached in 3 hours when an oral dose of 960 mg twice daily for 15 days has been given to patients. In the same conditions, Vemurafenib presents a Cmax of 62 mcg/ml and AUC of 601 mcg h/ml. It is unknown how food affects the absorption of vemurafenib. It presents an accumulation ratio of 7.36 after repeating doses of 960 mg
Toxicity
In the few toxicity reports, it has been shown an increased in the development of cutaneous squamous cell carcinomas or acceleration in pre-existant tumor growth.
Description
In August 2011, the United States FDA approved vemurafenib (PLX- 4032, RO-5185426) for the treatment of patients with metastatic melanoma with the BRAFV600E mutation. Vemurafenib has been developed as a targeted therapy for patients with the BRAF gene mutation since oncogenic B-raf signaling is implicated in approximately 50% of melanomas. Vemurafenib was identified based on an initial high-throughput screen followed by the extensive use of structure-based drug design. Vemurafenib is a potent inhibitor of B-RafV600E kinase (IC50=13 nM) compared to its potency against wildtype B-raf (IC50=160 nM) and is fairly selective versus a panel of 200 kinases. It does inhibit other kinases (RAF1, SRMS, ACK1, MAP4K5, and FGR) and mutant B-raf kinases (BRAFV600K, BRAFV600D, and BRAFV600R) with enzyme IC50's of <100 nM.
The Uses of PLX4032
Vemurafenib (PLX4032, RG7204) is a novel and potent inhibitor of B-RafV600E with IC50 of 31 nM
What are the applications of Application
Vemurafenib is a novel and orally bioavailable ATP-competitive inhibitor of B-RAFV600E, potent and with an IC50 of 31 nM.
Indications
Vemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on BRAF in the valine located in the exon 15 at codon 600, this mutation is denominated as V600E. The V600E mutation, a substitution of glutamic acid for valine, accounts for 54% of the cases of cutaneous melanoma. Vemurafenib approval was extended in 2017, for its use as a treatment of adult patients with Erdheim-Chester Disease whose cancer cells present BRAF V600 mutation. Erdheim-Chester disease is an extremely rare histiocyte cell disorder that affects large bones, large vessels, central nervous system, as well as, skin and lungs. It is reported an association of Erdheim-Chester disease and V600E mutation.
Background
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
Pharmacokinetics
BRAF activation results in cell growth, proliferation, and metastasis. BRAF is an intermediary molecule in MAPK whose activation depends on ERK activation, elevation of cyclin D1 and cellular proliferation. The mutation V600E produces a constitutively form of BRAF. Vemurafenib has been shown to reduce all activation markers related to BRAF; in clinical trials, vemurafenib treatment showed a reduction of cytoplasmic phosphorylated ERK and a cell proliferation driven by Ki-67. Studies also reported decrease in MAPK-related metabolic activity. All the different reports indicate thet Vemurafenib generates an almost complete inhibition of the MAPK pathway.
Metabolism
Vemurafenib is metabolized by CYP3A4 and the metabolites make up 5% of the components in plasma. The parent compound makes up for the remaining 95%.
Properties of PLX4032
Density | 1.46 |
storage temp. | -20°C |
solubility | Soluble in DMSO (up to 100 mg/ml) |
form | White powder. |
color | White or off-white |
Safety information for PLX4032
Computed Descriptors for PLX4032
New Products
3-N-BOC-(S)-AMINO BUTYRONITRILE 4-Piperidinopiperidine N-Benzyl-3-hydroxypiperidine 2-Methyl-4-nitrobenzoic acid 2-(4-bromophenyl)-2-methylpropanoic acid 4-Acetyl-2-methylbenzoicacid Acetyl-meldrum's acid Ethyl-4-Pyrazole carboxylate 2,6-Pyridinedimethanol 5,7-Dichloro-3H-Imidazo[4,5-B]Pyridine 5-Bromo-2-Methoxy-4-Methyl-3-Nitropyridine 2-Fluoro-5-Iodopyridine 2-Fluoro-5-Methylpyridine 2-Chloro-3-Bromo-5-Amiopyridine METHYL-4-(BUTYRYLAMINO)3-METHYL-5-NITROBENZOATE TRANS-CYCLOBUTANE-1,2- DICARBOXYLIC ACID 5-Nitro indazole R-(-)-5-(2-AMINO-PROPYL)-2-METHOXY-BENZENESULFONAMIDE 1,3-cyclohexanedione 4-Aminophenaethylalchol (S)-(+)-4-BENZYL-2-OXAZOLIDINONE 3-NITRO-5-ACETYL IMINODIBENZYL 4-FLUORO PHENYL MAGNESIUM BROMIDE 1.0 M IN THF 1-HYDROXY-4-METHYL6-(2,4,4-TRI METHYL PHENYL)-2-PYRIDONE MONO ETHANOL AMINE(PIROCTONE OLAMINE)Related products of tetrahydrofuran
![](https://img.chemicalbook.in/CAS/GIF/763113-22-0.gif)
![](https://img.chemicalbook.in/CAS/20180808/GIF/871700-17-3.gif)
![](https://img.chemicalbook.in/CAS/GIF/1195765-45-7.gif)
![](https://img.chemicalbook.in/CAS/GIF/1032350-13-2.gif)
![](https://img.chemicalbook.in/CAS/GIF/606143-52-6.gif)
![](https://img.chemicalbook.in/CAS/20180808/GIF/129830-38-2.gif)
![](https://img.chemicalbook.in/CAS/GIF/698387-09-6.gif)
You may like
-
2-Bromo-5-Iodopyridine 73290-22-9 98%View Details
73290-22-9 -
141-86-6 98%View Details
141-86-6 -
4-Amino-2-Chloropyridine 14432-12-3 98%View Details
14432-12-3 -
16867-03-1 2-Amino-3-Hydroxypyridine 98%View Details
16867-03-1 -
2,3-Diamino-5-Chloropyridine 25710-20-7 98%View Details
25710-20-7 -
13466-41-6 98%View Details
13466-41-6 -
Ammonium HexachloropalladateView Details
19168-23-1 -
50-00-0 Formalin; Methanal 0.99View Details
50-00-0